🔗 Share this article

As America continues making sweeping changes to its vaccine recommendations, a particular individual has emerged in a surprising turn: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines during the pandemic and has concentrated on possible fatalities after Covid immunization in her recent position at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Health officials planned to announce radical revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US at odds with much of the international standard with insufficient data for benefit. The planned update has been pushed back until the new year.

Instead of the director of the vaccine center, Høeg is scheduled to address the audience at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

Consolidating Power at the Agency

This interim role could signify a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back previously authorized vaccines at the FDA.

The new acting director has often pushed for discontinuing some childhood shot schedules in the US so as to align more like Denmark, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – traditionally the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been standard for former heads of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “grasp regulatory frameworks and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she lacks the kind of background that previous people who headed CBER have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock pointed out.

“The public just focuses on the new drug program, but the generic program clears numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one have to be supervised,” she said. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a major management element to the job, which supervises more than 5,000 employees. “It is a massive administrative position, if you execute it properly,” the former official concluded.

Response and Contentious Policies

Regarding questions about Dr. Høeg's credentials and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a representative stated that the “concerns stem from incorrect assumptions”.

“Her experience matches the functions of her job,” the official explained, noting the months Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's new fast-track approval initiative, a disputed rapid therapy clearance system that allegedly concerned her preceding directors. “How are these drugs being picked for this voucher program? Who takes the calls?” Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards laxer regulations of all drugs, aside from shots.”

Established Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if problematic, history, critics observe. She authored a research paper using unverified public submissions to assess the frequency of heart inflammation following COVID-19 immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the incoming government featured changing rules for recently developed shots and discontinuing “non-essential” immunizations, she stated after the election on a online show. At the FDA, Dr. Høeg has according to sources suggested excluding adolescent males from receiving COVID-19 vaccines.

“She is an all-around ideologue who commences with her preconceived notions and tailors the evidence to accommodate the data in a highly misleading, untruthful fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|